The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Experts unite to strengthen awareness and advanced care for multiple sclerosis: Our Bureau, Bengaluru Tuesday, January 20, 2026, 16:50 Hrs [IST] Multiple Sclerosis Society of Indi ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...

This is a preview. Log in through your library . Abstract Antigen-specific therapies hold promise for treating autoimmune diseases such as multiple sclerosis while avoiding the deleterious side ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

ETHealthworld.com brings latest multiple sclerosis news, views and updates from all top sources for the Indian Health industry.

Bengaluru Chapter, in collaboration with the Rotary Action Group Against Multiple Sclerosis (RAGAMS), hosted an awareness and ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

AUGS Overactive Bladder Symptoms in Patients With Multiple Sclerosis Patients with multiple sclerosis have significant rates of overactive bladder symptoms, yet they are not being evaluated or treated ...

Twelve Medical Groups Oppose UHC Copay Accumulator Program In an Oct. 7 letter to UHC, the 12 groups acknowledged that the drugs targeted by the accumulator policy are expensive. "However, they are ...